http://truthonthemarket.com/2006/11/03/the-ftcs-noerr-pennington-report/ Academic commentary on law, business, economics and more Tue, 14 Feb 2012 19:40:24 +0000 hourly 1 http://wordpress.com/ http://truthonthemarket.com/2006/11/03/the-ftcs-noerr-pennington-report/#comment-6331 Fri, 03 Nov 2006 21:38:39 +0000 http://www.truthonthemarket.com/2006/11/03/the-ftcs-noerr-pennington-report/#comment-6331 [...] Update:  Josh Wright at Truth on the Market has also noticed this report and blogs that This should prove to be an important document.  Properly limiting the scope of Noerr-Pennington immunity is a critical task for antitrust enforcement because, unlike the transitory anticompetitive effects caused by the actions of private firms, potentially anticompetitive acts carried out through abuse of governmental process can be executed cheaply and the effects durable. In any event, the report will be mandatory reading for my antitrust course next semester. [...]

]]> http://truthonthemarket.com/2006/11/03/the-ftcs-noerr-pennington-report/#comment-6330 Fri, 03 Nov 2006 17:23:10 +0000 http://www.truthonthemarket.com/2006/11/03/the-ftcs-noerr-pennington-report/#comment-6330 I did not beat you by much (although I now notice that I have to reset the blog’s clock due to daylight savings time). I too am still reading and digesting the report. Nonetheless, I will go out on a limb and predict that – although not mentioned by name in the report (or at least I have not seen it) – it will be cited by those parties who object brand name pharmaceutical companies filing multiple “citizen petitions” objecting to generic companies’ ANDA applications. See, for example, http://www.gphaonline.org/AM/Template.cfm?Section=Home&CONTENTID=1933&TEMPLATE=/CM/HTMLDisplay.cfm

]]>